Advanced diagnostics Target hospitals and labs focusing on ultra-sensitive biomarker detection who can benefit from Single Molecule Counting to improve early disease detection and monitoring; position Singulex Clarity as a premium, automated platform for high-sensitivity immunoassays.

Regulatory progress Leverage the 510(k) and CE marks to approach US and European commercial buyers; emphasize ongoing infectious and inflammatory disease assay development to expand catalog and address unmet clinical needs.

Strategic partnerships Propose collaborations with pharmaceutical companies and clinical research organizations for companion diagnostics and translational studies aligned with Singulex technology to unlock co-development and validation funding.

Global expansion Exploit existing Europe availability and plan to scale in North American and other markets by highlighting Clarity platform automation, potential for point-of-care adaptations, and reduced time-to-result for infectious disease assays.

Financial leverage Highlight scalable revenue potential from mid-size diagnostics labs (ASCs, reference labs) and emphasize cost-per-test advantages at high sensitivity; reference past funding and strategic partnerships to support sales discussions and risk mitigation.